Citations

Showing 10 of 108073 citations.

American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines
Hallemeier, Christopher L. , Sharma, Navesh , Anker, Christopher J. , Lee, Percy, Williams, Vonetta M. , Kennedy, Timothy J., Jethwa, Krishan R. , Kumar, Rachit , Russo, Suzanne , Jethwa, Krishan , Small, William , Hallemeier, Christopher Leigh , Selfridge, Jennifer Eva , Lee, Percy , Jabbour, Salma K , Liu, David M. , Kim, Ed, Tchelebi, Leila T. , Russo, Suzanne

Mayo Clinic

Cancer | July 6, 2023 | Volume: 129 | Issue: 20 | Pages: 3193-3212

10.1002/cncr.34931 | PMID 37409678 Get It

AbstractThe liver is a common site of cancer metastases. Systemic therapy is widely accepted as the standard treatment for liver metastases (LM), although select patients with liver oligometastases may be candidates for potentially curative liver resection. Recent data support the role of nonsurgical local therapies such as ablation, external beam radiotherapy, embolization, and hepatic artery infusion therapy for management of LM. Additionally, for patients with advanced, symptomatic LM, local therapies may provide palliative benefit. The American Radium Society gastrointestinal expert panel, including members representing radiation oncology, interventional radiology, surgical oncology, and medical oncology, performed a systemic review and developed Appropriate Use Criteria for the use of nonsurgical local therapies for LM. Preferred Reporting Items for Systematic reviews and Meta‐Analyses methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established consensus methodology (modified Delphi). A summary of recommendations is outlined to guide practitioners on the use of nonsurgical local therapies for patients with LM.
Magnetic Resonance Imaging Analysis Demonstrates Improved Reliability in Measuring Shoulder Glenoid Bone Loss Using a Two‐Thirds Glenoid Height Technique Compared to the “Best‐fit Circle”
Makovicka, Justin L. , Moore, M. Lane , Pollock, Jordan R. , Rodriguez, Marina , Shaha, James S., Haglin, Jack M. , Tokish, John M. , Moore, M Lane , Pollock, Jordan Riley

Mayo Clinic

Arthroscopy | July 6, 2023 | Volume: 40 | Issue: 3 | Pages: 666-671

10.1016/j.arthro.2023.06.048 | PMID 37419223 Get It

Purpose To evaluate the superior to inferior glenoid height as a reliable reference in best‐fit circle creation for glenoid anatomy. Methods The morphology of the native glenoid was evaluated using magnetic resonance imaging (MRI) in patients without shoulder instability. Using T1 sagittal MRI images, 2 reviewers independently estimated glenoid size using the two‐thirds technique and the “best‐fit circle” technique at 2 different times. A Student t ‐test was used to determine significant difference between the two methodologies. Inter‐ and intra‐rater reliability were calculated using interclass and intraclass coefficients. Results This study included 112 patients. Using the results of glenoid height and “best‐fit circle” diameter, the diameter of the “best‐fit circle” was found to intersect the glenoid line at 67.8% of the glenoid height on average. We found no significant difference between the 2 measures of glenoid diameter (27.6 vs 27.9, P = .456). The interclass and intraclass coefficients for the two‐third method were 0.85 and 0.88, respectively. The interclass and intraclass coefficients for the perfect circle methods were 0.84 and 0.73, respectively. Conclusions We determined that the diameter of a circle placed on the inferior glenoid using the “best‐fit circle” technique corresponds to 67.8% of the glenoid height. Additionally, we found that constructing a perfect circle using a diameter equal to two‐thirds the height of the glenoid may improve intraclass reliability. Level of Evidence Level IV, retrospective cohort study.
Outcomes of Frontal Sinus Stenting With Steroid Impregnated Microsponge Versus Steroid-Eluting Implant
Brar, Tripti , Brown, Adam , Miglani, Amar , Marino, Michael J. , Marino, Michael J , Lal, Devyani

Mayo Clinic

American Journal of Rhinology & Allergy | July 6, 2023 | Volume: 37 | Issue: 6 | Pages: 679-685

10.1177/19458924231186901 | PMID 37408359 Get It

Background Mometasone-eluting poly-L-lactide-coglycolide (MPLG) is available commercially for frontal sinus ostium (FSO) stenting. An alternative chitosan polymer-based drug delivery microsponge is also available at a lower cost per unit. Objective To compare the outcomes of MPLG stents versus triamcinolone-impregnated chitosan polymer (TICP) microsponge in frontal sinus surgery. Methods Patients who underwent endoscopic sinus surgery from December 2018 to February 2022 were reviewed to identify those with the intraoperative placement of TICP microsponge or MPLG stent in the FSO. FSO patency was evaluated by endoscopy at follow-up. Twenty-two-item sinonasal outcome test (SNOT-22) was also recorded, and complications were noted. Results A total of 68 subjects and 96 FSOs were treated. TICP was first used in August 2021 and MPLG in December 2018. MPLG placement in a Draf 3 cavity was excluded since TICP had not been used during Draf 3 procedure. Both cohorts (TICP 20 subjects, 35 FSOs; MPLG 26 subjects, 39 FSOs) had similar clinical characteristics. At a mean total follow-up of 249.2 days for TICP and 490.4 days for MPLG, FSO patency was 82.9% and 87.1%, respectively ( P = .265). At an equivalent follow-up of 130.6 days in TICP and 154.0 days in MPLG, patency was 94.3% and 89.7%, respectively ( P = .475). Both groups showed significant reductions in SNOT-22 ( P < .001). MPLG demonstrated crusting within the FSO at 1 month (none in TICP). Conclusion FSO patency for both stents was similar, although TICP had significantly lower costs per unit. Additional comparative trials may be helpful for guiding clinicians on the appropriate clinical situations for the use of these devices.
Lung Epithelial Cell Line Immune Responses to Pneumocystis
Kottom, Theodore J. , Carmona, Eva M. , Carmona, Eva M , Kottom, Theodore J , Limper, Andrew H.

Mayo Clinic

Journal of Fungi | July 6, 2023 | Volume: 9 | Issue: 7 | Pages: 729

10.3390/jof9070729 | PMID 37504718 Get It

Pneumocystis sp. are fungal pathogens and members of the Ascomycota phylum. Immunocompetent individuals can readily eliminate the fungus, whereas immunocompromised individuals can develop Pneumocystis jirovecii pneumonia (PJP). Currently, over 500,000 cases occur worldwide, and the organism is listed on the recently released WHO fungal priority pathogens list. Overall, the number of PJP cases over the last few decades in developed countries with the use of highly effective antiretroviral therapy has decreased, but the cases of non-HIV individuals using immunosuppressive therapies have significantly increased. Even with relatively effective current anti-Pneumocystis therapies, the mortality rate remains 30–60% in non-HIV patients and 10–20% during initial episodes of PJP in HIV/AIDS patients. Although the role of alveolar macrophages is well studied and established, there is also well-established and emerging evidence regarding the role of epithelial cells in the immune response to fungi. This mini review provides a brief overview summarizing the innate immune response of the lung epithelium and various continuously cultured mammalian cell lines to Pneumocystis.
Prevalence of Infectious Agents Causing Abortion in Pregnant Women Using Serological Tests and Histopathological Analysis
Mahmoud, Ahmed , Hagag, Howaida M., Ismail, Khadiga Ahmed , Alharthi, Abeer Muslih, Altalhi, Amal A. , Jaafer, Najwa F., Alharthi, Hassna H., Elwethenani, Ahmed A, Khan, K., Al-ajmani, Seham Hazza, Altalhi, Alaa Khader S., Alghamdi, Abdullah , Althobaiti, Naïf Saad, Ramadan, Reem Amr, Khalifa, Osama M., Mahmoud, Ahmed M , Altalhi, Amal Amer, Alharthi, Hassna H., Khalifa, Osama M.

Mayo Clinic

Applied Microbiology | July 6, 2023 | Volume: 3 | Issue: 3 | Pages: 698-708

10.3390/applmicrobiol3030048 Get It

Background: Abortion is a spontaneous loss of pregnancy before 20 weeks. Approximately 42 million pregnancies end in abortion. The maternal infections that are transmissible from mother to fetus are caused by many pathogens, of which the TORCH complex contributes majorly to neonatal and infant deaths globally. The aim of this study is to detect the prevalence and types of infectious causes of abortion. One hundred aborted women admitted to King Faisal Medical Complex Maternity Hospital in Taif City between the period of 2018 and 2020 were enrolled in this study. The serological test reports (TORCH panel), as well as reports of hematological (CBC) and chemical parameters, were obtained from laboratory management system databases, reviewed, and then analyzed. The H&E-stained microscopic slides of their product of conception (POC) were examined under a microscope and compared with histopathological reports. The prevalence of TORCH infections was 8% in aborted women. Hepatitis B virus (HBV) and mixed TORCH infections constituted the highest percentage of TORCH pathogens in aborted women, constituting 6%. The most detected histopathological finding in seropositive cases (50%) was POC, with mixed inflammatory infiltrates and chronic endometritis, while in seronegative aborted women, POC was normal (64.1%). There is a statistically significant increase in the mean count of white blood cells in seropositive women. Therefore, it is important to provide health campaigns to bring awareness to the population about the risk factors of infectious agents to be avoided, especially during pregnancy.
Facial Morphometrics in Black Celebrities: Contemporary Facial Analysis Using an Artificial Intelligence Platform
Salinas, Cristina A., Liu, Alice , Sharaf, Basel , Sharaf, Basel A, Sharaf, Basel A

Mayo Clinic

Journal of Clinical Medicine | July 6, 2023 | Volume: 12 | Issue: 13 | Pages: 4499

10.3390/jcm12134499 | PMID 37445534 Get It

The diversity of patients pursuing facial aesthetic and facial gender-affirming surgery (FGAS) is increasing, yet there is a paucity of objective guidelines to facilitate surgical decision-making in patients of color. We conducted a quantitative analysis of black celebrities using standardized frontal photos of 21 female and 21 male celebrities. Celebrities were chosen from popular entertainment magazines and websites, including People Magazine, the Internet Movie Database (IMDb), Cosmopolitan, and Essence. For each celebrity, 100 facial landmarks were detected through a facial analysis artificial intelligence (AI) program. Black males had greater facial height, bizygomatic width, lower facial height, and bigonial width than females. However, the facial height to bigonial width ratio was similar between genders and approximated the golden ratio (1.618). Female faces demonstrated a greater mid-face height to total facial height proportion, and males had a greater lower facial height proportion. Females exhibited an upward-slanted medial brow and shorter total eyebrow length, nose height, and alar width. Forehead height above the lateral brow was greater in males, while central forehead height was similar to females. This is the first study that has utilized AI to provide ethnicity-specific facial morphometrics relevant to facial rejuvenation and FGAS in the black population.
Mesenchymal Stem/Stromal Cells Therapy for Metabolic Syndrome: Potential Clinical Application?
Huang, Xiuyi , Liu, Yunchong , Li, Zilun , Lerman, Lilach O.

Mayo Clinic

Stem Cells | July 6, 2023 | Volume: 41 | Issue: 10 | Pages: 893-906

10.1093/stmcls/sxad052 | PMID 37407022 Get It

Abstract Mesenchymal stem/stromal cells (MSCs), a class of cells with proliferative, immunomodulatory, and reparative functions, have shown therapeutic potential in a variety of systemic diseases, including metabolic syndrome (MetS). The cluster of morbidities that constitute MetS might be particularly amenable for the application of MSCs, which employ an arsenal of reparative actions to target multiple pathogenic pathways simultaneously. Preclinical studies have shown that MSCs can reverse pathological changes in MetS mainly by inhibiting inflammation, improving insulin resistance, regulating glycolipid metabolism, and protecting organ function. However, several challenges remain to overcome before MSCs can be applied for treating MetS. For example, the merits of autologous versus allogeneic MSCs sources remain unclear, particularly with autologous MSCs obtained from the noxious MetS milieu. The distinct characteristics and relative efficacy of MSCs harvested from different tissue sources also require clarification. Moreover, to improve the therapeutic efficacy of MSCs, investigators have explored several approaches that improved therapeutic efficacy but may involve potential safety concerns. This review summarized the potentially useful MSCs strategy for treating MetS, as well as some hurdles that remain to be overcome. In particular, larger-scale studies are needed to determine the therapeutic efficacy and safety of MSCs for clinical application.
Spectral flow cytometry identifies distinct nonneoplastic plasma extracellular vesicle phenotype in glioblastoma patients
Aibaidula, Abudumijiti, Fain, Cori E. , Garcia, Luz Cumba, Wier, Annelise, Bouchal, Samantha M. , Jung, M. Katherine , Johnson, Aaron J. , Parney, Ian F. , Aibaidula, Abudumijiti Zack, Jung, Mi-Yeon, Parney, Ian F , Bouchal, Samantha M , Bauman, Megan M. J. , Sarkaria, Jann N. , Johnson, Aaron J.

Mayo Clinic

Neuro-Oncology Advances | July 5, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdad082 | PMID 37638345 Get It

Abstract Background Glioblastoma (GBM) is the most common malignant brain tumor and has a poor prognosis. Imaging findings at diagnosis and in response to treatment are nonspecific. Developing noninvasive assays to augment imaging would be helpful. Plasma extracellular vesicles (EVs) are a promising biomarker source for this. Here, we develop spectral flow cytometry techniques that demonstrate differences in bulk plasma EV phenotype between GBM patients and normal donors that could serve as the basis of a liquid biopsy. Methods Plasma EVs were stained for EV-associated tetraspanins (CD9/CD63/CD81), markers indicating cell of origin (CD11b/CD31/CD41a/CD45), and actin/phalloidin (to exclude cell debris). EVs were analyzed using spectral flow cytometry. Multiparametric analysis using t-distributed stochastic neighbor embedding (t-SNE) and self-organizing maps on flow cytometry data (FlowSOM) was performed comparing GBM and normal donor (ND) plasma EVs. Results Size exclusion chromatography plus spectral-based flow cytometer threshold settings enriched plasma EVs while minimizing background noise. GBM patients had increased CD9+, CD63+, CD81+, and myeloid-derived (CD11b+) EVs. Multiparametric analysis demonstrated distinct surface marker expression profiles in GBM plasma EVs compared to ND EVs. Fifteen plasma EV sub-populations differing in size and surface marker expression were identified, six enriched in GBM patients and two in normal donors. Conclusions Multiparametric analysis demonstrates that GBM patients have a distinct nonneoplastic plasma EV phenotype compared to ND. This simple rapid analysis can be performed without purifying tumor EVs and may serve as the basis of a liquid biopsy.
Clinicoradiologic Criteria for the Diagnosis of Stroke-like Episodes in MELAS
Khasminsky, Vadim , Auriel, Eitan , Luckman, Judith, Eliahou, Ruth, Inbar, Edna , Pardo, Keshet, Landau, Yuval E., Barnea, Rani , Mermelstein, Maor , Shelly, Shahar , Naftali, Jonathan , Peretz, Shlomi , Landau, Yuval, Shahar, Shelly

Mayo Clinic

Neurology Genetics | July 5, 2023 | Volume: 9 | Issue: 4 | Pages: No page available

10.1212/nxg.0000000000200082 | PMID 37426458 Get It

Clinical Examination of the Cranial Nerves
Singh, Rohin , Moore, Marlena, Lee, Yeonsoo Sara , Hudson, Miles , Lee, Yeonsoo S, Sara Lee, Yeonsoo , Singh, Rohin , Pollock, Jordan Riley , Bendok, Bernard R. , Patel, Naresh P.

Mayo Clinic

New England Journal of Medicine | July 5, 2023 | Volume: 389 | Issue: 1 | Pages: No page available

10.1056/nejmvcm2103640 | PMID 37407003 Get It